Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
|
31118602 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 160 smokers diagnosed with COPD (GOLD I-IV, 40 subjects of each GOLD stage) and 40 smokers at risk (GOLD 0; median age of 60 years old; Q1:56;Q3:65; 135 males and 65 females) underwent non-contrast, non-electrocardiography synchronized chest computerised tomography.
|
30651888 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 370 patients with COPD were grouped based on disease severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) I-IV criteria.
|
30887750 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Twelve COPD subjects (GOLD stages I-IV) participated in this study and underwent HPX-MRI, V/Q-SPECT/CT, high-resolution CT, and PFTs.
|
30552482 |
2019 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 310 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stages I-IV) who presented at the outpatient clinic of the Showa University Hospital from September 2014 through January 2015, 119 were collected and assigned into 2 groups according to their history of exacerbation: exacerbators and nonexacerbators.
|
29317813 |
2018 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Global initiative for chronic Obstructive Lung Disease stage I-IV COPD patients electronically transmitted respiratory symptom diaries to research staff daily between December 2006 and April 2009.
|
28331305 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, which was nested within a prospective cohort study, the serum levels of PAI-1 were cross-sectionally measured in 74 stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease [GOLD] Stages I-IV) and 18 controls without lung disease.
|
28356730 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
94 COPD patients (aged 43-86 years, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages I-IV) were examined with V/P SPECT and spirometry.
|
28603413 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 2,088 patients with COPD (61.1% male; mean [SD] age, 65.3 [8.2] years, GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5, and 10.5%, respectively) were included, of which 184 patients (8.8%; GOLD stage I-IV: 5.1, 7.4, 11.1, and 9.5%, respectively, vs. 5.9% in patients with GOLD stage 0 in the COPD and Systemic Consequences-Comorbidities Network) had PAD.
|
27532739 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients were predominantly elderly man (N = 71; 98%), with a mean age of 72 years with COPD GOLD stage I-IV.
|
28993936 |
2017 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In ever-smokers, odds ratios for COPD in homozygotes versus noncarriers were 1.3 (95% CI 1.2-1.4) for Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages I-IV, 1.4 (95% CI 1.2-1.6) for GOLD II-IV and 1.7 (95% CI 1.3-2.1) for GOLD III-IV.
|
22441734 |
2012 |
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three out of about 50 of the most abundant receptor GR gene polymorphisms were investigated in a case-control study which included 207 patients with chronic bronchitis or COPD (mean FEV1 50.5% predicted, GOLD I-IV) and 106 age matched healthy subjects (mean FEV1 101.8% predicted).
|
20156759 |
2009 |
Chronic Obstructive Airway Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated DC infiltration in small airways by immunohistochemistry in patients with COPD (stage I-IV), never-smokers, and smokers without COPD.
|
17332482 |
2007 |